APJ-targeted cardiometabolic therapeutics program
preclinicaldrug program · medium
Develop therapies for cardiometabolic diseases using APJ as a therapeutic target, with listed lead indications including heart failure with preserved ejection fraction, obesity, and sarcopenia.
Therapeutic drug discovery program targeting APJ.
Company site lists APJ as a therapeutic target and identifies heart failure with preserved ejection fraction, obesity, and sarcopenia as lead indications; VitaDAO assessment describes Zoe Biosciences as an early-stage therapeutic biotech with two target-centered programs.
APJ therapeutic program
undiscloseddrug program · medium
Develop therapies for cardiometabolic disease, with listed lead indications including HFpEF, obesity, and sarcopenia.
Therapeutic program targeting APJ.
Listed by Zoe Biosciences as one of its therapeutic target areas; VitaDAO assessment describes Zoe as having two target-centered programs.
Heart failure (HFpEF) program
undiscloseddrug program · medium
Develop therapies for heart failure with preserved ejection fraction as part of Zoe Biosciences' cardiometabolic disease pipeline.
Therapeutic development targeting PAI-1 and APJ.
Listed as a lead indication on the company science/pipeline page.
Obesity program
undiscloseddrug program · medium
Develop therapies for obesity as part of Zoe Biosciences' cardiometabolic disease pipeline.
Therapeutic development targeting PAI-1 and APJ.
Listed as a lead indication on the company science/pipeline page.
PAI-1-targeted cardiometabolic therapeutics program
preclinicaldrug program · medium
Develop therapies for cardiometabolic diseases using PAI-1 as a therapeutic target, with listed lead indications including heart failure with preserved ejection fraction, obesity, and sarcopenia.
Therapeutic drug discovery program targeting PAI-1.
Company site lists PAI-1 as a therapeutic target and identifies heart failure with preserved ejection fraction, obesity, and sarcopenia as lead indications; VitaDAO assessment describes Zoe Biosciences as an early-stage therapeutic biotech with two target-centered programs.
PAI-1 therapeutic program
undiscloseddrug program · medium
Develop therapies for cardiometabolic disease, with listed lead indications including HFpEF, obesity, and sarcopenia.
Therapeutic program targeting PAI-1.
Listed by Zoe Biosciences as one of its therapeutic target areas; VitaDAO assessment describes Zoe as having two target-centered programs.
Sarcopenia program
undiscloseddrug program · medium
Develop therapies for sarcopenia as part of Zoe Biosciences' cardiometabolic disease pipeline.
Therapeutic development targeting PAI-1 and APJ.
Listed as a lead indication on the company science/pipeline page.
